See more : Cadence Design Systems, Inc. (CDS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Therma Bright Inc. (TBRIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Therma Bright Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Lectra SA (LSS.PA) Income Statement Analysis – Financial Results
- Ashford Hospitality Trust, Inc. (AHT-PI) Income Statement Analysis – Financial Results
- IOI Properties Group Berhad (5249.KL) Income Statement Analysis – Financial Results
- VALUE CREATION CO LTD (9238.T) Income Statement Analysis – Financial Results
- Abengoa, S.A. (AGOAF) Income Statement Analysis – Financial Results
Therma Bright Inc. (TBRIF)
About Therma Bright Inc.
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 172.75K | 251.02K | 250.86K | 770.03K | 43.81K | 38.54K | 37.83K | 6.50K |
| Cost of Revenue | 614.00 | 0.00 | 75.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00K | 372.71K | 121.96K | 281.02K | 27.43K | 24.08K | 23.72K | 0.00 |
| Gross Profit | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.27K | 0.00 | 0.00 | 0.00 | 0.00 | 31.75K | -121.69K | 128.90K | 489.01K | 16.38K | 14.45K | 14.11K | 6.50K |
| Gross Profit Ratio | 97.64% | 100.00% | 45.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.31% | 0.00% | 0.00% | 0.00% | 0.00% | 18.38% | -48.48% | 51.38% | 63.50% | 37.38% | 37.50% | 37.30% | 100.00% |
| Research & Development | 9.69K | 446.58K | 805.54K | 1.37M | 13.08K | 60.67K | 92.49K | 97.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 570.00 | 9.05K | 58.65K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 0.00 | 0.00 | 756.94K | 0.00 | 0.00 | 0.00 | 0.00 | 704.05K | 706.22K | 26.73K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 68.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.04K | 0.00 | 0.00 | 0.00 | 0.00 | 2.12K | 23.22K | 115.00 |
| SG&A | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.10M | 1.30M | 1.22M | 1.96M | 1.15M | 706.17K | 729.44K | 26.84K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.16M | 3.63M | 5.90M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.11M | 1.32M | 1.31M | 2.10M | 1.18M | 713.41K | 931.71K | 28.10K |
| Cost & Expenses | 1.16M | 3.63M | 5.98M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 352.30K | 440.91K | 317.77K | 262.41K | 193.63K | 1.25M | 1.70M | 1.43M | 2.38M | 1.21M | 737.49K | 955.43K | 28.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 0.00 | 0.00 |
| Interest Expense | 8.60K | 13.44K | 1.38K | 0.00 | 17.40K | 18.91K | 8.74K | 0.00 | 0.00 | 3.90K | 643.97K | 550.99K | 473.02K | 423.68K | 312.72K | 267.74K | 0.00 | 0.00 | 0.00 | 1.27K | 0.00 | 0.00 |
| Depreciation & Amortization | 99.51K | 75.38K | 53.85K | 57.98K | 2.98K | 2.79K | 76.00 | 247.00 | 22.82K | 3.90K | 1.80M | 2.30M | 473.02K | 423.68K | 8.89K | 20.34K | 97.21K | 136.62K | 35.73K | 21.00K | 202.27K | 163.63K |
| EBITDA | -2.34M | -3.68M | -5.73M | -8.55M | -606.31K | -400.24K | -1.24M | -965.10K | -205.55K | -350.59K | 710.24K | 1.43M | -262.41K | -193.63K | -1.07M | -1.82M | -1.09M | -1.47M | -1.13M | -1.35M | -466.92K | -715.33K |
| EBITDA Ratio | -8,988.07% | -15,393.76% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,768.46% | -3,096.93% | -4,288.52% | -20,514.16% | 0.00% | 0.00% | 0.00% | 0.00% | -618.36% | -567.40% | -433.19% | -190.85% | -2,582.01% | -1,759.32% | -1,890.80% | 2,184.40% |
| Operating Income | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | -400.03K | -1.24M | -965.34K | -205.55K | -354.49K | -1.08M | -868.76K | -735.43K | -617.31K | -1.09M | -1.44M | -1.18M | -1.61M | -1.17M | -698.95K | -917.60K | -21.60K |
| Operating Income Ratio | -4,355.04% | -15,076.51% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,769.00% | -3,097.72% | -4,288.52% | -20,742.36% | 0.00% | 0.00% | 0.00% | 0.00% | -633.18% | -575.50% | -471.94% | -208.59% | -2,663.56% | -1,813.82% | -2,425.45% | -332.17% |
| Total Other Income/Expenses | -1.32M | -164.64K | -196.39K | -74.54K | -19.56K | -21.90K | -8.81K | -247.00 | -472.00 | -1.88K | 1.15M | 1.73M | -41.06K | 0.00 | -420.04K | -390.97K | -228.63K | -95.70K | 17.40K | -589.48K | 3.76K | -42.30K |
| Income Before Tax | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -1.84M | -1.41M | -1.70M | -1.15M | -1.96M | -959.90K | -21.65K |
| Income Before Tax Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -731.25% | -563.07% | -221.02% | -2,623.86% | -5,079.90% | -2,537.27% | -332.93% |
| Income Tax Expense | 0.00 | 0.00 | 1.38K | -178.58K | 17.40K | 18.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 312.72K | 267.74K | 195.65K | 133.18K | 20.67K | 361.30K | -295.99K | -9.50K |
| Net Income | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -2.10M | -1.61M | -1.84M | -1.15M | -2.32M | -663.91K | -12.15K |
| Net Income Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -837.92% | -641.07% | -238.31% | -2,623.86% | -6,017.49% | -1,754.88% | -186.82% |
| EPS | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
| Weighted Avg Shares Out (Dil) | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
Therma Bright inks exclusive license agreement for AI4LYF's Digital Cough Technology to detect respiratory diseases
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF), the developer of the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other medical device technologies, revealed that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF's Digital Cough...
Therma Bright to invest up to US$2.5M in developer of a groundbreaking ischemic stroke treatment
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has signed a share purchase agreement to buy up to a 25% stake in Inretio Ltd, an Israel-based company developing a medical device to treat ischemic stroke. Under the terms of the deal, Therma Bright...
Therma Bright plots a course to build on 2022 product development in end-of-year shareholder letter
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF), the developer of the smart-enabled AcuVid COVID-19 rapid antigen saliva test, has released an end-of-year shareholder update with comments from CEO Rob Fia. "2022 was a busy year for Therma Bright with many accomplishments and...
Therma Bright invests in novel treatment using inhaled statins to treat respiratory conditions
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) announced that it has entered into an agreement to acquire an interest in a novel technology utilizing inhaled statins to treat respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), and acute lung inflammatory...
Therma Bright to explore Digital Cough Technology with AI maker AI4LYF for app to detect COVID-19
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has entered into a letter of intent with AI4LYF LLC for the exclusive licensing rights for a digital cough-based diagnosis screening technology. The Toronto-based medical device maker said its Digital Cough Test (DCT) is...
Therma Bright receives temporary billing codes for Venowave, allowing reimbursement through Medicare and Medicaid
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has received new temporary Pricing, Data Analysis and Coding (PDAC) billing codes for its Venowave product, giving it access to reimbursement through Medicare and Medicaid. Initial US sales were made under an existing reimbursement...
Therma Bright receives payment for initial Venowave orders in the US; explores global opportunities for the DVT prevention device
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it had received payment for the first sales of Venowave, its compact, lightweight deep vein thrombosis (DVT) prevention device. Initial US sales were made under an existing reimbursement code which required preapproval from the...
Therma Bright updates on progress of applications to FDA and Health Canada for its AcuVid COVID-19 rapid antigen saliva test
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) has said it continues to communicate with the US Food & Drug Administration (FDA) regarding its application for Emergency Use Authorisation (EUA) for its AcuVid COVID-19 rapid antigen saliva test. The medical diagnostics and device...
Therma Bright submits Health Canada application for its AcuVid COVID-19 rapid antigen saliva test for point-of-care use
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has submitted an application to Health Canada for its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The Toronto-based company said the application includes all the updated data from the...
Therma Bright provides update on US FDA application for its AcuVid COVID-19 rapid antigen saliva test
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has submitted follow-up answers and reformatted data to the US Food and Drug Administration (FDA) for the company's Emergency Use Authorization (EUA) application for its AcuVid COVID-19 Rapid Antigen Saliva Test. The Toronto-based...
Source: https://incomestatements.info
Category: Stock Reports